Gene Expression Signature of Primary Imatinib-Resistant Chronic Myeloid Leukemia Patients

Leukemia - United Kingdom
doi 10.1038/sj.leu.2404270
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Nature

Related search

Decreased Expression of microRNA‑214 Contributes to Imatinib Mesylate Resistance of Chronic Myeloid Leukemia Patients by Upregulating ABCB1 Gene Expression

Experimental and Therapeutic Medicine
MedicineCancer ResearchImmunologyMicrobiology
2018English

Therapeutic Drug Monitoring of Imatinib for Chronic Myeloid Leukemia Patients

2012English

Characteristics of the TCR Vβ Repertoire in Imatinib-Resistant Chronic Myeloid Leukemia Patients With ABL Mutations

Science China Life Sciences
GeneticsMolecular BiologyEnvironmental ScienceBiochemistryBiological SciencesAgricultural
2015English

Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid Leukemia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

Treatment Options for Patients With Chronic Myeloid Leukemia Who Are Resistant to or Unable to Tolerate Imatinib

Clinical Therapeutics
Pharmacology
2010English

Micro-Rna Response to Imatinib Mesylate in Patients With Chronic Myeloid Leukemia

Haematologica
Hematology
2010English

Imatinib and Plasmacytoid Dendritic Cell Function in Patients With Chronic Myeloid Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2004English

A Four-Gene LincRNA Expression Signature Predicts Risk in Multiple Cohorts of Acute Myeloid Leukemia Patients

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2017English

Long-Term Safety and Efficacy of Dasatinib in the Treatment of Chronic-Phase Chronic Myeloid Leukemia Patients Resistant or Intolerant to Imatinib

Blood and Lymphatic Cancer: Targets and Therapy
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy